News

This segment of Liver Lineup features an in-depth discussion on transplant access with MELD 3.0 and new research about potential disparities it introduces.

This segment of Diabetes Dialogue spotlights the new guidelines’ broad suggestion regarding alcohol, as well as how organizations may interpret it.

These data suggest improvement of care for patients with skin cancer and frail skin through geriatrician use, along with a nurse-led geriatric assessment, may be beneficial.

Lumateperone 42 mg plus antidepressants boosts remission rates and sustains symptom improvement in MDD patients, says Michael E. Thase, MD.

This analysis suggests TYK2 (tyrosine kinase 2) inhibitors may have a dual therapeutic potential to address both skin symptoms of psoriasis and comorbid depressive symptoms.

New CureGN findings and an interview with Andrew Vissing, MD, highlight distinct glomerular disease outcomes in adolescents and young adults compared with pediatric and adult patients

Weintraub discusses how patients with overweight or obesity, regardless of T2D, will regain weight in varying degrees after discontinuing therapy.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

In a 26-week head-to-head study, adjunctive seltorexant led to less weight gain and improved insulin sensitivity trends compared with quetiapine XR in MDD with insomnia.

Post hoc MODIFY data showed no significant eGFR or UACR benefit with lucerastat, though exploratory signals appeared in patients with baseline renal impairment.

Recent research shows a substantial portion of US youths have increased risk of cardiometabolic diseases due to obesity and overweight.

Investigators assessed the post-procedure reparative impact of a combination of vitamin C, E, and ferulic acid treatment in patients in China with atrophic acne scars.

Upton discusses an open-label trial showing a 30 mg per nut very low-dose oral immunotherapy strategy increased multi-nut tolerance and remained safe in children.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clearances, in this week’s essential news roundup.

Wang discusses results from a recent study, comparing multiple forms of intravenous and oral iron supplements in female patients with heavy menstrual bleeding.

Higher accuracy lung biopsy could make a strong impact on lung cancer diagnoses and outcomes.

In this analysis, the rates of survival of primary cutaneous melanoma were evaluated based on the delay of definitive surgery.

Reau and Brown discuss emerging research in liver transplantation and hepatocellular carcinoma from AASLD The Liver Meeting 2025.

In children with CKD and iron deficiency anemia, iron polymaltose complex improved hemoglobin and TSAT, while liposomal iron was better tolerated.

A 12-week study found that combining CBT with quetiapine lowered suicide risk more than quetiapine alone in adults with depressive or bipolar disorders.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review tech updates from Sequel Med Tech, Diabeloop, and Medtronic.

Sinha explains current unmet needs in mild Crohn’s, the shortcomings of steroids for these patients, and what benefits a fasting-mimicking diet may offer.

A population-based analysis suggests age and sex specific eGFR percentiles and a web-based calculator can identify CKD risk before diagnostic thresholds.

This study analyzed the Chronic Urticaria Registry (CURE), evaluating CSU treatment patterns and looking into unmet needs in real-world practice.

Reduced IgE binding and blunted basophil activation in response to Gal d 1 and Gal d 2 suggest that heat-treated egg proteins could improve the safety of OIT for egg-allergic patients.

A cohort study of patients from the Women’s Health Study has highlighted the direct correlation between lipoprotein(a) levels and cardiovascular risk in healthy patients.

A smartphone-based patient-caregiver educational program was evaluated in its impact on relapse rates in children with moderate-to-severe atopic dermatitis.

Berotralstat becomes the first once-daily oral prophylactic option for long-term prevention of hereditary angioedema in children aged 2–11 years.